Silexion Therapeutics Corp. has announced its financial results for the first quarter of 2025, ending March 31. The company reported raising over $9 million in gross funds during this period. This includes approximately $5.0 million from a public offering of ordinary shares, pre-funded warrants, and ordinary warrants, alongside an additional $0.9 million from the exercise of certain warrants. Furthermore, Silexion generated approximately $3.3 million from a warrant exercise inducement transaction in late January. In March 2025, the company successfully retired a promissory note valued at $1.25 million through cash payments and share issuances. Operationally, Silexion made significant strides in its preclinical pipeline, particularly with its SIL204 program. The company reported groundbreaking data from orthotopic pancreatic cancer models, where subcutaneously administered SIL204 reduced primary tumor growth and metastatic spread. Specifically, there was a ~70% reduction in tumor cell numbers in the AsPC-1 (KRAS G12D) model and ~80% reduction in the BxPC-3 model by day 28. These results indicate potential advancements in treating KRAS-driven cancers, with Silexion's SIL204 showing promise in reducing tumor and metastatic burdens. The company is now focused on advancing this pipeline toward clinical development, supported by strategic collaborations and a strengthened financial position.